Acute effects of the sigma-2 receptor agonist siramesine on lysosomal and extra-lysosomal proteolytic systems in lens epithelial cells.
OBJECTIVE
The aim of the present study was to examine the effects of the sigma-2 receptor agonist, siramesine, on morphology, growth, cell death, lysosomal function, and effects on extra-lysosomal proteolytic systems in human lens epithelial cells.


METHODS
Human lens epithelial cells in culture were exposed to siramesine and examined for morphological changes using Nomarski optics or calcein. Lysosomes were evaluated using acridine orange and Magic Red (RR-cresyl violet). Nuclear morphology was studied using Hoechst 33342 and propidium iodide. Enzymatic activities in living cells or cell lysates were studied using fluorogenic substrates.


RESULTS
Siramesine at low concentrations increased the cytoplasmic proteolytic activity of the proteasome and the calpain system. Effects were also observed with respect to lysosomal morphology, acidity and function. In addition, activation of caspase-3 and the appearance of nuclei with an apoptotic morphology was found.


CONCLUSIONS
Siramesine at low concentrations affects lens epithelial cells with perturbations of the major proteolytic systems and lysosomal morphology, resulting in caspase activation and cell death. Siramesine may be a possible substance for the treatment or prevention of posterior capsular opacification (PCO).
Jonhede
S
S
Institute of Biomedicine, Department of Medical Chemistry and Cell Biology, University of Gothenburg, Gothenburg, Sweden.
Petersen
A
A
Zetterberg
M
M
Karlsson
J-O
JO
D000143:Acids / Q000378:metabolism; D020169:Caspases / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003593:Cytoplasm / Q000201:enzymology; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation / Q000187:drug effects; D004847:Epithelial Cells / Q000187:drug effects / Q000648:ultrastructure; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D007908:Lens, Crystalline / Q000166:cytology*; D008247:Lysosomes / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D010447:Peptide Hydrolases / Q000187:drug effects / Q000378:metabolism*; D017480:Receptors, sigma / Q000819:agonists*; D013141:Spiro Compounds / Q000008:administration & dosage*
D000143:Acids; D007211:Indoles; C109644:Lu 28-179; D017480:Receptors, sigma; D013141:Spiro Compounds; C106107:sigma-2 receptor; D010447:Peptide Hydrolases; D020169:Caspases
Mol Cancer Ther. 2006 Jul;5(7):1807-16
16891467
J Neurosci. 1995 Jan;15(1 Pt 1):117-34
7823122
Cancer Res. 2007 Mar 1;67(5):2217-25
17332352
J Pak Med Assoc. 2008 Oct;58(10):550-2
18998307
Curr Pharm Des. 2006;12(30):3857-76
17073684
J Pharmacol Exp Ther. 2007 Jul;322(1):341-50
17460149
Invest Ophthalmol Vis Sci. 1999 Jan;40(1):261-4
9888455
Arch Ophthalmol. 2009 Apr;127(4):555-62
19365040
Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003738
17636731
Curr Opin Investig Drugs. 2001 Feb;2(2):266-70
11816842
Cancer Res. 2004 Jul 15;64(14):4875-86
15256458
Eur J Pharmacol. 2002 May 17;443(1-3):207-9
12044812
Cancer Res. 2007 Jul 15;67(14):6708-16
17638881
Neuropharmacology. 2002 Jul;43(1):95-100
12213263
Eur J Pharmacol. 1995 May 15;278(2):151-60
7671999
Cancer Res. 2002 Jan 1;62(1):313-22
11782394
Cancer Res. 1997 Jan 1;57(1):156-61
8988058
J Cataract Refract Surg. 2004 Jan;30(1):58-66
14967269
Ophthalmic Res. 2005 Nov-Dec;37(6):318-27
16138003
J Am Chem Soc. 2008 Oct 1;130(39):12953-60
18767848
Cancer Res. 2005 Oct 1;65(19):8975-83
16204071
Autophagy. 2008 May;4(4):487-99
18305408
Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1403-8
15790908
Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):106-13
15322732
J Med Chem. 1995 May 26;38(11):1998-2008
7783131
Cell Calcium. 2006 Jul;40(1):23-8
16687172